RecruitingPhase 2Phase 3NCT06504732

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumors and Gastric Cancer

Sponsor

SUNHO（China）BioPharmaceutical CO., Ltd.

Enrollment

90 participants

Start Date

Aug 15, 2024

Study Type

INTERVENTIONAL

Conditions

Stomach Neoplasms Solid Tumor

Summary

The safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with or without the CAPEOX regimen in unsystematically treated subjects with HER2-expressing advanced/metastatic colorectal or gastric cancers (including adenocarcinomas of the gastro-esophageal junction) or HER2-hypo-expressing advanced/metastatic solid tumors. The efficacy of IAH0968 in combination with the CAPEOX regimen versus trastuzumab in combination with the CAPEOX regimen in subjects with HER2-positive advanced/metastatic gastric cancer, including gastro-esophageal junction adenocarcinoma, was then assessed by progression-free survival (PFS) according to the Research and Evaluation Criteria for the Evaluation of Efficacy in Solid Tumors (RECIST) 1.1.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called IAH0968 combined with a chemotherapy regimen (CAPEOX: capecitabine and oxaliplatin) for patients with HER2-positive stomach cancer. HER2-positive means the cancer cells have too many copies of a protein that makes them grow faster. The study aims to find the right dose and see how effective this combination is. **You may be eligible if...** - You are 18–75 years old with confirmed HER2-positive advanced or metastatic gastric or gastroesophageal junction cancer - You have not yet received systemic treatment for your advanced cancer (previous adjuvant chemotherapy ended more than 6 months ago) - You are in reasonably good physical condition - You have measurable tumors that can be assessed on scans **You may NOT be eligible if...** - You have already been treated with systemic therapy for advanced disease - You are not HER2-positive (as confirmed by testing) - You have serious uncontrolled medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIAH0968

Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.

Locations(2)

The First Hospital of China Medical University

Shenyang, Liaoning, China

The First Hospital of China Medical University

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06504732

Related Trials

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

NCT056455233 locations

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT0661958738 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT064413315 locations